Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2 Study of SL-701, a Subcutaneously Injected Multivalent Glioma-Associated Antigen Vaccine, in Adult Subjects With Recurrent Glioblastoma Multiforme

NCT02078648 is registered in ClinicalTrials.gov with Stemline Therapeutics, Inc. as lead sponsor.

NCT NCT02078648
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02078648 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2 Study of SL-701, a Subcutaneously Injected Multivalent Glioma-Associated Antigen Vaccine, in Adult Subjects With Recurrent Glioblastoma Multiforme
Lead sponsor
Stemline Therapeutics, Inc.
Phase
Phase 1/2
Overall status
Completed
Start date
May 31, 2014
Completion date
January 22, 2018
Enrollment
74 (actual)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

adult brain glioblastoma, glioblastoma multiforme